HIV Drugs: Big success in the fight against AIDS, USFDA approves Indian pharma company’s generic drug

New Delhi| There has been a major breakthrough against HIV infection and AIDS. In fact, America’s health regulatory body has approved the use of generic medicines of an Indian pharma company. Indian pharma company Lupine, which has received approval, has issued a statement saying that the US Food and Drug Administration (USFDA) has currently temporarily approved Lupine’s medicine used in the treatment of HIV.

The company issued a statement giving information
The statement said that this approval has been given under the US President’s Emergency Plan for AIDS Relief. The medicines approved by Mumbai-based pharma company Lupine include Abacavir, Dolutegravir and Lamivudine tablets. These medicines are the generic version of Triumeq PD tablets, a medicine from ViiV Healthcare Company. These medicines will be manufactured at Lupine Company’s plant in Nagpur and will be supplied to middle and low income group countries.

Abacavir (60 mg), Dolutegravir (5 mg), Lamivudine (30 mg) are medicines with a fixed dose, which AIDS patients must take as a tablet every day. These medicines are effective for newborns up to three months with HIV-1 infection and these newborns should weigh at least six kilos. Lupine Executive Director and Global CFO SBU Ramesh Swaminathan issued a statement expressing happiness over getting the approval of UFFDA.

Registry and treatment clinic of patients suffering from rare diseases started in Kerala
Kerala Health Minister Veena George said on Friday that the registry of patients suffering from rare diseases in the state will start from this year. Speaking after inaugurating a workshop for experts in rare disease treatment, George said the government aims to prevent rare diseases. He said that a rare disease treatment clinic will be established in Kozhikode this year. The government is trying to save the affected children. He noted that, currently, the survival rate of children undergoing treatment for SMA (spinal muscular atrophy) had exceeded 90 per cent.

The state health minister said that ‘the state government aims to identify congenital disabilities and ensure special treatment for children. In February 2024 in Kerala, the state government launched the CARE scheme for rare diseases. In 2024, enzyme replacement therapy for rare diseases was started at S A T Hospital “Currently, 106 patients are receiving expensive treatment under the plan”, George said. Through the Shalabham project, congenital disabilities in children are identified and treated. The Hridayam scheme, which focuses on detecting and treating congenital heart diseases, has seen 7,916 children undergo heart surgery’